A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Orion Corporation (“Orion”) and Invenra Inc. (“Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered ...

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, ...